[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"breast-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:breast-neoplasm":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,24,0,[8,61,93,128,184,211,231,255,283,310,338,358,378,405,435,471,498,525,586,612,660,679,704,726],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":60},"100613993","evaluating-an-ai-based-mobile-application-for-chemotherapy-support-in-breast-cancer-patients-100613993",false,"NCT07273812","Evaluating an AI-Based Mobile Application for Chemotherapy Support in Breast Cancer Patients","Evaluating an AI-Based Mobile Application for Chemotherapy Support in Breast Cancer Patients: A Randomized Controlled Trial","AI-ChemoApp","Inclusion Criteria:\n\n* Confirmed diagnosis of breast cancer stages I, II, or III.\n* Patients must be currently scheduled to initiate their first-ever cycle of chemotherapy.\n* Age 18 years or older.\n* Ability to understand and provide informed consent.\n* Possession of a smartphone (Android or iOS) and functional digital literacy, defined as the ability to independently navigate mobile applications, read on-screen text in Arabic, and input daily health data. (for the intervention group).\n* Willingness to comply with study procedures and follow-up schedules.\n* Ability to communicate in Arabic, as the mobile application and chatbot will be developed in Arabic.\n\nExclusion Criteria:\n\n* Patients with Stage IV (Metastatic) breast cancer.\n* Patients receiving concurrent hormonal therapy during the chemotherapy phase, to isolate chemotherapy-induced adverse events.\n\nPatients with cognitive impairment or severe psychiatric disorders that would preclude effective interaction with the mobile application or questionnaire completion.\n\n* Patients receiving palliative care where symptom management is the sole focus and active chemotherapy is not being administered with curative or life prolonging intent.\n* Patients participating in other interventional clinical trials that might confound the outcomes of this study.\n* Patients with severe comorbidities that could significantly impact their ability to participate or bias outcome measures.","FEMALE","18 Years",{"count":20,"type":21},130,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn if an Arabic-language mobile application that uses artificial intelligence (AI) can help women with breast cancer during chemotherapy. The app is designed to give personalized support by reminding participants about their medications, teaching them how to manage treatment side effects, and alerting their healthcare team about serious symptoms.\n\nThe main questions this study aims to answer are:\n\n1. Does the AI-based mobile app provide accurate and safe recommendations for the patients?\n2. Does using the AI-based mobile app help lower treatment-related symptoms and side effects compared to usual care?\n3. Does the app help participants take their medications more regularly?\n4. Does it increase participants' understanding and satisfaction with the information they receive about their treatment?\n\nResearchers will compare two groups:\n\nGroup 1: Participants who use the AI-based mobile app plus usual oncology care. Group 2: Participants who receive usual care only.\n\nParticipants will:\n\n1. Use the mobile app daily for 12 weeks while receiving chemotherapy.\n2. Complete short questionnaires about symptoms, medication use, and quality of life at the start and end of the study.\n3. Report any problems or feedback about using the app. The AI app is for support and education only. It does not make treatment decisions. All information from the app will be reviewed by oncologists and pharmacists to ensure participant safety.",[27,28,29,30,31,32,33],"Breast Cancer","Breast Neoplasm","Chemotherapy-Related Toxicities","Medication Adherence","Quality of Life in Cancer Patients","Accuracy of AI App","Symptom Management",[35,36,37,38,39,40,41,42,43,44,45,46,47],"Artificial Intelligence","Mobile Application","digital health","supportive care","chemotherapy","patient education","Symptom Monitoring","Human-in-the-Loop AI","Breast Cancer Chemotherapy","Oncology","Arabic Language App","Pharmacy Iraq","Randomized Controlled Trial","RECRUITING","2026-06-10",{"date":51,"type":52},"2026-06-12","ACTUAL",{"date":54,"type":52},"2026-06-01",{"date":56,"type":21},"2026-11-06",{"name":58,"class":59},"Dena h. Al-Tameemi","OTHER",1,{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":69,"enrollmentInfo":70,"targetDuration":4,"studyType":22,"phases":72,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":60},"100484012","phase-2-fudan-university-shanghai-cancer-center-breast-cancer-precision-platform-series-study--neoadjuvant-therapy-100484012","NCT05582499","Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy","Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (FASCINATE-N)","FASCINATE-N","Inclusion Criteria:\n\n* Histologically confirmed invasive breast cancer of clinical stage T1-4N1-3M0 or cT2-4N0M0;\n* Age between18-70 years;\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1;\n* ER, PR and HER2 status were measured by immunohistochemistry (IHC);\n* LVEF≥55%；\n* Definition of SNF subtypes: SNF subtypes confirmed by digital pathology of H\\&E slices;\n* Triple negative subtyping: On the basis of triple-negative pathological diagnosis, AR, cluster of differentiation 8 (CD8) and Forkhead Box C1 (FOXC1) were combined to define the subtyping;\n* At least one measurable lesion according to RECIST version 1.1\n* Normal organ and marrow function: Hemoglobin (HB) ≥90 g\u002FL (No blood was transfused within 14 days), Absolute neutrophil count ≥ 1500\u002FμL, Platelets ≥ 75,000\u002FμL, Total bilirubin ≤ 1.5 x ULN), aspartate aminotransferase (AST) (SGOT) and alanine aminotransferase (ALT) (SGPT) ≤ 3 x ULN, creatinine \\\u003C 1 x ULN, endogenous creatinine clearance \\> 50 ml\u002Fmin (Cockcroft-Gault formula);\n* Non-pregnant and non-lactating, fertile female subjects were required to use a medically approved contraceptive method for the duration of the study treatment and at least 3 months after the last use of the study drug;\n* Ability to understand and willingness to sign a written informed consent\n\nExclusion Criteria:\n\n* Previous cytotoxic chemotherapy, endocrine therapy, biological therapy or radiotherapy for any reason;\n* Patients with New York Heart Association (NYHA) grade II or above heart disease (including grade II);\n* Patients with severe systemic infections or other serious diseases;\n* Patients with known allergy or intolerance to the study drug or its excipients;\n* Other malignant tumors in the past 5 years, except cured cervical carcinoma in situ and non-melanoma skin cancer;\n* Pregnant or lactating patients of childbearing age who refused to take appropriate contraceptive measures during the course of the study;\n* Participated in other trial studies within 30 days before the administration of the first dose of the study drug;\n* Patients who were judged by the investigator to be unsuitable for this study.","70 Years",{"count":71,"type":21},716,[73],"PHASE2","The purpose of this study is to establish a prospective, single-center platform research based on clinical subtypes to explore precision neoadjuvant therapy in patients with operable breast cancer who met the indications for neoadjuvant chemotherapy and by the update of basic translational research in the center, especially the refinement of typing, the discovery of new targets and the development of novel targeted drugs, verified the effectiveness of new targeted drugs in neoadjuvant therapy.",[28,27,76,77,78,79,80,81,82,83],"Breast Tumors","Triple-Negative Breast Cancer (TNBC)","HER2-positive Breast Cancer","HER2-negative Breast Cancer","Hormone Receptor Positive Tumor","Hormone Receptor Negative Tumor","Early-stage Breast Cancer","Locally Advanced Breast Cancer","2026-05-22",{"date":86,"type":52},"2026-05-28",{"date":88,"type":52},"2022-11-01",{"date":90,"type":21},"2029-09",{"name":92,"class":59},"Fudan University",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":101,"minAge":18,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":22,"phases":104,"briefSummary":106,"conditions":107,"keywords":111,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":127},"100521670","phase-3-study-of-the-bria-imt-regimen-and-cpi-vs-physicians-choice-in-advanced-metastatic-breast-cancer-100521670","NCT06072612","Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.","Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice in Advanced Metastatic Breast Cancer.","BRIA-ABC","Inclusion Criteria:\n\n1. Be ≥ 18 years of age.\n2. Have signed informed consent.\n3. Have histological confirmation of breast cancer with either locally recurrent unresectable and\u002For metastatic lesions, and have failed prior therapy:\n\n   * Patients with persistent disease and local recurrence must not be amenable to local treatment.\n   * For patients with metastatic disease, late-stage MBC with no meaningful alternative therapies available and the following class specific treatment histories:\n\n     1. Human epidermal growth factor 2 (HER2) positive must be previously treated with at least 3 regimens containing at least two anti-HER2 and at least one chemotherapy containing regimen.\n     2. Estrogen receptor (ER), progesterone receptor (PR) positive tumors: must be refractory to hormonal therapy demonstrated by progression on at least 2 hormonal agents in 2 separate lines of hormone directed therapy.\n     3. Triple Negative tumors: Must have exhausted all curative intent therapies including at least 2 prior chemotherapy regimens, which can include regimens in neoadjuvant and adjuvant settings.\n     4. Cancers with known germline or genomic actionable targets, e.g. g\u002FmBRCA, must have been treated with all tumor directed indicated treatment e.g. PARPi, if tolerated.\n     5. HER2 low patients, in addition to the appropriate therapies based on ER\u002FPR status and germline or genomic actionable targets, must also have received at least one HER2-targeted agent approved for treatment of HER2 low patients.\n     6. HER2 negative tumors must be refractory to hormonal therapy (if indicated) and previously treated with at least 2 chemotherapy regimens.\n     7. Patients with new or progressive breast cancer metastatic to the brain will be eligible provided:\n\n        * The brain metastases must be clinically stable (without evidence of progressive disease by imaging for at least 4 weeks prior to first dose)\n        * There is no need for steroids and patients have not had steroids for at least 2 weeks prior to the first dose\n        * Tumor is not impinging on Middle Cerebral Artery\u002Fspeech-motor strip\n        * If surgically debulked, must be healed with at least 3 weeks since surgery prior to the first dose\n4. Has expected survival of at least 4 months.\n5. ECOG performance status of 0, 1 or 2\n\nExclusion Criteria:\n\n1. Concurrent or recent chemotherapy, immunotherapy or major surgery within 21 days prior to the first dose.\n2. Radiotherapy within 14 days of the first dose of study treatment.\n3. Toxicity of prior therapy that has not recovered to ≤ Grade 1 or baseline (with the exception of any grade of alopecia and anemia not requiring transfusion support).\n4. Any toxicity to prior CPI that was grade 3 or higher unless it has been successfully treated (e.g. hypothyroidism or hypopituitarism treated with replacement therapy), .\n5. Toxicity to prior CPI that has not resolved to grade 1 or less except for stable asymptomatic endocrinopathies.\n6. History of clinical hypersensitivity to the designated therapy as specified in the protocol, including the proposed TPC, beef, or to any components used in the preparation of SV- BR-1-GM.\n7. History of hypersensitivity to any of the therapies proposed for treatment in this study.\n8. Serum creatinine OR Measured OR calculated Creatinine Clearance (CrCl) (GFR can also be used in place of creatinine or CrCl) \\>2.0 × ULN or \\\u003C30 mL\u002Fmin for participants with creatinine levels \\>2.0 × institutional ULN.\n9. Absolute granulocyte count \\\u003C1000; platelets \\\u003C80,000; hemoglobin ≤ 7 g\u002FL.\n10. Bilirubin ≥ 2 × ULN unless conjugated bilirubin ≤ ULN; alkaline phosphatase \\>5x upper limit of normal (ULN); ALT\u002FAST \\>3x ULN. For patients with hepatic metastases, ALT\u002FAST \\>5x ULN is exclusionary.\n11. INR or PT or aPTT \\> 1.8 × ULN, unless the participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants.\n12. Receiving any medication listed in the prohibited medication section of the protocol.\n13. Proteinuria \\>2+ on urinalysis\n14. A history or presence of an abnormal electrocardiogram (ECG) that, in the Investigator's opinion, is clinically meaningful. Screening corrected QT interval (QTc) interval \\>480 milliseconds is excluded (corrected by Fridericia or Bazett formula). In the event that a single QTc is \\>480 milliseconds, the participant may enroll if the average QTc for the 3 ECGs is \\\u003C480 milliseconds.\n15. New York Heart Association stage 3 or 4 cardiac disease.\n16. A pericardial effusion of moderate severity or worse.\n17. Symptomatic pleural effusion or ascites. A participant who is clinically stable following treatment for these conditions (including therapeutic thoraco- or paracentesis) is eligible.\n18. Any woman of childbearing potential (i.e., has had a menstrual cycle within the past year and has not been surgically sterilized), unless she agrees to take appropriate precautions to avoid becoming pregnant during the study and has a negative serum pregnancy test within 7 days prior to starting treatment.\n19. Men must have been sterile or, if they were potentially fertile\u002Freproductively competent, should take appropriate precautions to avoid fathering a child for the duration of the study.\n20. Women who are pregnant or nursing.\n21. Known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years of study entry with the exception of cured basal cell or squamous cell carcinoma of the skin, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive or indolent malignancy, or cancers from which the participant has been disease-free for \\> 1 year, after treatment with curative intent.\n22. Patients who have uncontrolled HIV or have clinical or laboratory features indicative of AIDS.\n23. Have a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (doses exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment.\n24. Have an active autoimmune disease that has required systemic treatment in past year (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is allowed.\n25. Known active HAV, HBV, or HCV infection, as defined by elevated transaminases with the following serology: positivity for HAV IgM antibody, anti-HCV, anti-HBc IgG or IgM, or HBsAg (in the absence of prior immunization).\n26. Active infections requiring systemic therapy within the past 14 days.\n27. Patients with severe psychiatric disease (e.g., schizophrenia, bipolar, or borderline personality disorder) or other clinically progressive major medical problems, unless approved by the Investigator in consultation with the Medical Monitor.\n28. Has received a live vaccine within 28 days of the first dose of study drug.\n29. Patients may not be on a concurrent clinical trial, unless approved by the Investigator.","ALL",{"count":103,"type":21},404,[105],"PHASE3","This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \\[Retifanlimab\\], versus Treatment of Patients'\u002FPhysicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies available.",[27,108,28,109,110],"Metastatic Breast Cancer","Breast Cancer Metastatic","End Stage Cancer",[112,113,114,115,116],"Breast","metastatic","advanced","cancer","late line","2026-04-06",{"date":119,"type":52},"2026-04-07",{"date":121,"type":52},"2023-12-05",{"date":123,"type":21},"2028-06",{"name":125,"class":126},"BriaCell Therapeutics Corporation","INDUSTRY",79,{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":101,"minAge":18,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":60},"100536733","phase-2-tart-cherry-juice-as-a-dietary-supplement-for-the-prevention-of-paclitaxel-induced-neuropathy-100536733","NCT06268665","Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy","A Randomized Trial of Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy","Inclusion Criteria:\n\n* Histologically confirmed invasive breast or ovarian cancer (Stage I, II, III, or IV) as per AJCC 8th Edition, 2018 Staging Criteria.\n* Must be planning to receive paclitaxel weekly for 12 weeks (12 weeks total) as part of neoadjuvant, adjuvant, or metastatic cancer treatment.\n\n  * Concurrent biologic therapy (e.g., trastuzumab and pertuzumab) is allowed.\n  * Currently receiving hormone therapy, bisphosphonates, denosumab or LHRH-agonists is allowed.\n  * Concurrent use of immune checkpoint inhibitor therapy is allowed.\n  * (Neo)adjuvant chemotherapy with doxorubicin and cyclophosphamide is allowed.\n  * Concurrent use of carboplatin with weekly paclitaxel in the study is allowed.\n* May participate concurrently in other cancer trials.\n* Must be able to complete questionnaires in English or Spanish.\n* Age ≥ 18 years old at the time of consent.\n* ECOG performance status of 0 - 1 (Karnofsky scale ≥ 70%, see Appendix).\n* Ability to understand and the willingness to sign a written informed consent document.\n* Individuals of child-bearing potential must agree to use birth control (e.g., hormonal or barrier method; abstinence, an intrauterine device) prior - to study entry, for the duration of study participation (including dose interruptions), and for 3 months after the last dose of tart cherry juice supplement; or be surgically sterilized (e.g., hysterectomy or tubal ligation).\n* Patients with known human immunodeficiency virus (HIV) are allowed in the study, but HIV-positive patients must have:\n\n  * A stable regimen of highly active anti-retroviral therapy (HAART)\n  * No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\n  * A CD4 count above 250 cells\u002FµL and an undetectable HIV viral load on standard PCR-based tests within the last year.\n* Stated willingness to not drink any additional tart cherry or any cherry juice while on the study.\n* Ability and willingness to adhere to the study visit schedule and other protocol requirements\n\nExclusion Criteria:\n\n* Have received any prior therapy with taxanes, vinca alkaloids, eribulin, ixabepilone, or platinum. Doxorubicin is allowed (≥ 2 week washout period required).\n* Active or history of peripheral neuropathy, or any chronic diseases associated with peripheral neuropathy such as diabetes mellitus, alcohol use disorder, or systemic lupus erythematosus.\n* Currently taking anticoagulant medication.\n* Currently taking Vitamin E, glutamine, alpha lipoic acid, gabapentin, nortriptyline, amitriptyline or duloxetine. If a patient is taking any of these supplements\u002Fmedications, they must agree to stop at the time of registration. Multivitamins containing Vitamin E are allowed, however Vitamin E \\> 1,000 international units (IU) must be discontinued at the time of registration.\n* Patients may not use cold therapy gloves for chemotherapy induced neuropathy.\n* Known allergy to cherries.\n* Inability to swallow liquid.\n* Pregnant or breastfeeding individuals (lactating individuals must agree not to breast feed while taking study juice supplementation).\n* Any condition that would prohibit the understanding or rendering of informed consent.\n* Any condition that in the opinion of the investigator would interfere with safety or compliance while on trial.",{"count":136,"type":21},86,[73],"This is a single institution phase II randomized study evaluating the potential benefits of a supplement, tart cherry juice at high- versus low-doses, to prevent taxane induced peripheral neuropathy in breast and ovarian cancer patients undergoing paclitaxel chemotherapy.\n\nEligible participants enrolled onto the study will be block randomized in a 1:1 allocation to either the tart cherry juice high-dose group (Arm 1) or the tart cherry juice low-dose group (Arm 2).",[27,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,28,170,171,172,173,174],"Breast Cancer Stage I","Breast Cancer Stage II","Breast Cancer Stage III","Breast Cancer Stage IV","Invasive Breast Cancer","Ovarian Cancer","Ovarian Cancer Stage 1","Ovarian Cancer Stage II","Ovarian Cancer Stage III","Ovarian Cancer Stage IV","Ovarian Cancer Stage IA","Ovarian Cancer Stage IB","Ovarian Cancer Stage IC","Ovarian Cancer Stage 2","Ovarian Cancer Stage 3","Ovarian Cancer Stage IIIb","Ovarian Cancer Stage IIIC","Breast Cancer Stage IIIA","Breast Cancer Invasive","Breast Cancer, Stage IA","Breast Cancer, Stage IB","Breast Cancer Stage IIA","Breast Cancer Stage IIB","Breast Cancer Stage IIIB","Breast Cancer Stage IIIc","Cancer, Breast","Tumors, Breast","Mammary Cancer","Mammary Carcinoma","Breast Carcinoma","Malignant Breast Neoplasm","Malignant Tumor of Breast","Cancer of Ovary","Ovary Cancer","Ovary Neoplasm","2026-03-02",{"date":177,"type":52},"2026-03-04",{"date":179,"type":52},"2024-08-15",{"date":181,"type":21},"2027-12",{"name":183,"class":59},"University of California, Davis",{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":17,"minAge":192,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":22,"phases":195,"briefSummary":196,"conditions":197,"keywords":198,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":60},"100478105","cryoablation-vs-lumpectomy-in-t1-breast-cancers-100478105","NCT05505643","Cryoablation vs Lumpectomy in T1 Breast Cancers","COOL-IT: Cryoablation vs Lumpectomy in T1 Breast Cancers: A Randomized Controlled Trial With Safety Lead-in","COOL-IT","Inclusion Criteria:\n\n* Diagnosis of invasive ductal carcinoma of the breast (ER , Her-2 negative) that is grade 1 or 2 with intraductal component \\\u003C25%. Must be T1N0M0 (2 cm or less).\n* If DCIS is present in the biopsy specimen it should be \\\u003C25% of the tumor and should be contiguous with the IDC. (i.e. DCIS should not be a separate tumor from the IDC).\n* Oncotyping will be performed on T1b+Allred\\\u003C6\u002F8 and T1c tumors. Oncotype score in this subset of patients must be \\\u003C26 to be included in the trial.\n* At least 50 years of age.\n* Negative ipsilateral axillary assessment as determined either by (1) negative axillary ultrasound (2) negative sentinel lymph node biopsy or (3) negative percutaneous axillary node biopsy with no further clinical or imaging concern for nodal metastatic disease.\n* Able to understand and willing to sign an IRB-approved written informed consent document.\n\nExclusion Criteria:\n\n* Indication for neoadjuvant chemotherapy.\n* Prior history of breast cancer.\n* Breast augmentation.\n* Allergy to local anesthetics.\n* Pregnant or lactating. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry.\n* Tumoral involvement of skin or chest wall.","50 Years",{"count":194,"type":21},120,[24],"This trial studies the efficacy and safety of cryoablation in patients with low risk, early stage breast cancer. Cryoablation is a method of killing a tumor by freezing it. The standard approach for patients with this kind of cancer is a lumpectomy. This study will review the safety of the cryoablation procedure initially, followed by comparing cryoablation to lumpectomy in order to see if the cryoablation results in better disease control, complication rates, and quality of life.",[27,28],[199,200,201],"breast cancer","cryoablation","lumpectomy","2026-02-24",{"date":204,"type":52},"2026-02-27",{"date":206,"type":52},"2024-04-03",{"date":208,"type":21},"2033-04-30",{"name":210,"class":59},"Washington University School of Medicine",{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":101,"minAge":18,"maxAge":4,"enrollmentInfo":217,"targetDuration":4,"studyType":219,"phases":4,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":60},"100423872","quantitative-microvasculature-imaging-for-breast-cancer-detection-and-monitoring-100423872","NCT04799535","Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring","Inclusion Criteria:\n\n* AIM 1: Patient volunteers, ages \\>= 18 with suspicious breast masses scheduled for breast biopsy, or at least two weeks or more after breast biopsy\n* AIM 2: Patient volunteers, ages \\>= 18 who have biopsy proven breast cancer and are going under neoadjuvant chemotherapy and\u002For endocrine therapy had their baseline MRI and\u002For ultrasound\n\nExclusion Criteria:\n\n* Patients with breast implants or any condition that does not allow proper use of ultrasound (US)",{"count":218,"type":21},550,"OBSERVATIONAL","This study evaluates the effectiveness of a breast ultrasound method for the diagnosis of breast cancer. Diagnostic procedures, such as breast ultrasound, may help find and diagnose breast cancer, and may help measure a patient's response to earlier treatment. The purpose of this research is to test the effectiveness of a new investigational breast ultrasound method to detect an abnormality in the breast, and assess response to breast cancer treatment.",[169,28],"2026-01-30",{"date":224,"type":52},"2026-02-03",{"date":226,"type":52},"2019-09-01",{"date":228,"type":21},"2027-11-29",{"name":230,"class":59},"Mayo Clinic",{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":17,"minAge":238,"maxAge":4,"enrollmentInfo":239,"targetDuration":4,"studyType":219,"phases":4,"briefSummary":241,"conditions":242,"keywords":243,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":254},"100567754","a-prospective-study-to-develop-and-clinically-validate-an-in-vitro-diagnostic-medical-device-that-uses-blood-to-classify-patients-at-high-risk-for-breast-cancer-100567754","NCT06672302","A Prospective Study to Develop and Clinically Validate an in Vitro Diagnostic Medical Device That Uses Blood to Classify Patients at High Risk for Breast Cancer","A Multi-center, Single Arm, Prospective Exploratory in Vitro Diagnostic Devices Clinical Performance Study to Evaluate of in Vitro Diagnostic Devices for Auxiliary Diagnosis That Classifies High-risk and Low Risk Patients With Breast Cancer by Analyzing Surface-enhanced Raman Spectroscopy (SERS) Profiles of Extracellular Vesicles (EVs) Extracted From Human Plasma Using Artificial Intelligence","Inclusion Criteria(Breast malignant nodule group)\n\n1. Korean nationality\n2. Voluntary written consent to participate in this clinical performance trial study\n3. Confirmed breast cancer through imaging\u002Fpathologic diagnostic tests\n4. Those who have been diagnosed with breast cancer at a stage prior to treatment and surgery, and who agree to participate in this study and are able to provide blood samples.\n5. Those whose lesions have been confirmed by conventional examination (breast ultrasound or mammography) and who fall into BI-RADS categories 4,5,6 and have undergone biopsy or are scheduled to undergo biopsy within 2 weeks.\n6. Those who meet the following demographic conditions A. Adult female, 40 years of age or older\n7. Those who can provide the following clinical information A. Age and biological sex B. Whether or not they have dense breasts C. Occupational information D. Pathological tumor size, Clinical tumor size, Pathological TNM staging, Clinical TNM staging, tumor location, breast cancer histology findings (breast cancer subtype) E. Family history and past history of cancer F. Breast-related diseases G. Chronic disease history\n\nInclusion Criteria(Breast benign nodule group)\n\n1. Korean nationality\n2. Voluntary written consent to participate in this clinical performance trial study\n3. Diagnosed with breast nodules through imaging\u002Fpathologic diagnostic tests\n4. Those who have been diagnosed with breast nodules and have agreed to participate in this study and are able to provide blood samples at a stage prior to treatment and surgery.\n5. Those whose lesions have been confirmed by conventional examination (breast ultrasound or mammography) and fall into BI-RADS categories 4,5,6 and have undergone biopsy or are scheduled for biopsy within 2 weeks\n6. Those who meet the following demographic conditions A. Adult female, 40 years of age or older\n7. Those who can provide the following clinical information A. Age and biological sex B. Whether or not they have dense breasts C. Occupational information D. Diagnosis, nodule size, and number of nodules E. Family history and past history of cancer F. Breast-related diseases G. Chronic disease history\n\nExclusion Criteria:\n\n1. Those who have been diagnosed with cancer (malignant tumor) of any type within 5 years of the date of consent and have undergone appropriate chemotherapy\u002Fradiation treatment or surgery.\n2. Those who are confirmed to have developed breast cancer due to metastasis from malignant tumors other than breast cancer\n3. Pregnant women\n4. Participation in a drug-related clinical trial within 3 months of the date of the informed consent form","40 Years",{"count":240,"type":21},330,"EXoPERT has developed a liquid biopsy-based in vitro diagnostic medical device that can diagnose cancer through blood. The in vitro diagnostic medical device for this clinical performance trial is a test device that applies a technology that measures Raman spectroscopic signals of extracellular vesicles in the blood and classifies high-risk and low-risk patients for breast cancer through artificial intelligence analysis.\n\nThe test device used in this clinical performance trial is expected to assist in the differential diagnosis of high-risk and low-risk breast cancer patients by developing a software algorithm for an in vitro diagnostic medical device for auxiliary diagnosis that classifies high-risk and low-risk breast cancer patients and confirming the clinical efficacy and safety of the device through this clinical performance trial.",[28],[112,27,244],"Neoplasm","2026-01-06",{"date":247,"type":52},"2026-01-08",{"date":249,"type":52},"2024-10-16",{"date":251,"type":21},"2026-12-31",{"name":253,"class":126},"EXoPERT",2,{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":261,"eligibilityCriteria":262,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":263,"targetDuration":4,"studyType":22,"phases":265,"briefSummary":266,"conditions":267,"keywords":268,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":281,"locationsCount":60},"100512248","health-economic-evaluation-of-an-adapted-physical-activity-program-for-women-with-breast-cancer-100512248","NCT05949983","Health Economic Evaluation of an Adapted Physical Activity Program for Women With Breast Cancer","Health Economic Evaluation of an Adapted Physical Activity Program for Women With Breast Cancer During the Active Phase of Treatment: a Randomized Controlled Trial","EMEAPA","Inclusion Criteria:\n\n* women with breast cancer\n* any type of breast cancer, all grades, all stages\n* during treatment: surgery +\u002F- chemotherapy +\u002F- radiotherapy +\u002F- hormone therapy\n\nExclusion Criteria:\n\n* World Health Organization (WHO) 4\n* Unstable angina\n* Uncontrolled Atrial fibrillation\n* Uncontrolled high blood pressure\n* Recent myocardial infarction or myocarditis or pericarditis or thromboembolic disease (less than 3 weeks)\n* Aortic stenosis or valve disease to operate\n* Cardiac or respiratory failure, with dyspnea at rest\n* Symptomatic anemia, thrombocytopenia\n* Lytic or painful bone metastases, Severe osteoporosis\n* Severe infectious syndrome,\n* Surgery in the last 3 weeks\n* Extreme fatigue, sharp pain, dizziness, disturbance of consciousness, severe undernutrition\n* Contraindication to the practice of an adapted physical activity programme\n* Currently involved or exclusion period of a interventional study or adapted Physical Activity program\n* Patient with protective measures (guardianship, curators, and deprivation of liberty).\n* Pregnancy or breastfeeding\n* Patient with severe functional limitations",{"count":264,"type":21},866,[24],"Adapted physical activity (APA) was recognized as a non-drug therapy by the French Health Authority (HAS) in 2011. Very few studies have examined the efficiency of APA programs during the active phase of treatment in cancer patients. The investigators assumed that non-drug therapy such as APA could improve the quality of life and reduces health costs. The main objective of this study is to assess the efficiency of a standardized APA program, as compared to conventional management including simple recommendations for the practice of physical activity in women in phase active breast cancer treatment.",[28],[269,270,271,272,273,274],"Physical Activity","Exercise","Exercise Therapy","Breast Neoplasms","Medical costs","Healthcare Costs","2025-12-23",{"date":277,"type":52},"2025-12-31",{"date":279,"type":52},"2024-12-23",{"date":181,"type":21},{"name":282,"class":59},"University Hospital, Toulouse",{"id":284,"slug":285,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":289,"eligibilityCriteria":290,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":69,"enrollmentInfo":291,"targetDuration":4,"studyType":22,"phases":293,"briefSummary":294,"conditions":295,"keywords":296,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":60},"100412596","preventing-chemotherapy-induced-peripheral-neuropathy-using-presiona-exercise-program-100412596","NCT04652609","Preventing Chemotherapy-induced Peripheral Neuropathy Using PRESIONA Exercise Program","Prevention of Chemotherapy-induced Peripheral Neuropathy With Therapeutic Exercise and Blood Flow Restriction Using PRESIONA Program","PRESIONA","Inclusion Criteria:\n\n* 18 years or older\n* HER2+ breast cancer diagnosis\n* On the waiting list to anticancer medical treatment (taxanes-based neoadjuvant chemotherapy)\n\nExclusion Criteria:\n\n* Previous diagnosis of cancer\n* Pregnant\n* Cardiac pathology\n* No symptoms or pathology that could be confused with neuropathy or related to diabetes\n* No recommendation from oncologist for therapeutic exercise practice",{"count":292,"type":21},25,[24],"The aim of this study is to determinate if therapeutic exercise with blood flow restriction (BFR) during neoadjuvant chemotherapy potentialy neurotoxic could prevent the onset of chemotherapy induced peripheral neuropathy (CIPN) comparing to usual care.",[28],[297,298,299,300],"Breast neoplasm","Breast cancer","Therapeutic exercise","Small Fiber Neuropathy","2025-11-15",{"date":303,"type":52},"2025-11-18",{"date":305,"type":52},"2021-01-01",{"date":307,"type":21},"2027-01-01",{"name":309,"class":59},"Universidad de Granada",{"id":311,"slug":312,"hasResults":11,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":316,"eligibilityCriteria":317,"healthyVolunteers":11,"sex":17,"minAge":238,"maxAge":4,"enrollmentInfo":318,"targetDuration":4,"studyType":219,"phases":4,"briefSummary":320,"conditions":321,"keywords":325,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":60},"100597148","surviving-daily-life-100597148","NCT07054723","Surviving Daily Life","Daily Stress Process and Daily Cognitive Performance Among Racially Diverse Breast Cancer Survivors: A Feasibility and Validation Study","GOCE","Inclusion Criteria:\n\nIndividuals must meet all of the following inclusion criteria in order to be eligible to participate in the study:\n\n* Individuals 40 or older\n* Five or more years after breast cancer diagnosis\n* Self-identified as Asian, Black, Latina, or white\n* Able to read in English, Spanish, or Chinese\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Under 40\n* Cannot provide informed consent",{"count":319,"type":21},30,"The primary goal of this project is to evaluate the feasibility of a 14-day mobile daily diary study among racially diverse breast cancer survivors. Further, the investigators will examine the validity and reliability of the daily stress and daily cognitive performance measures among breast cancer survivors. This pilot project will recruit 30 racially diverse breast cancer survivors (Asian, Black, Latina, and white; ages 40 and older; at least five years post-diagnosis) who are patients at the Sidney Kimmel Comprehensive Cancer Center. The daily diary survey questions will be available in English, Spanish, and Chinese to accommodate the preferred language of the target participants.",[322,323,27,169,28,324],"Stress","Cognitive Change","Cognitive Dysfunction",[326,327,328],"Mobile Survey","Daily Diary","Breast Cancer Survivors","2025-10-20",{"date":331,"type":52},"2025-10-22",{"date":333,"type":52},"2025-10-02",{"date":335,"type":21},"2026-10-31",{"name":337,"class":59},"Thomas Jefferson University",{"id":339,"slug":340,"hasResults":11,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":4,"eligibilityCriteria":344,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":345,"targetDuration":4,"studyType":22,"phases":347,"briefSummary":348,"conditions":349,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":60},"100520598","molecular-breast-imaging-guidance-for-breast-biopsy-for-patients-with-breast-abnormalities-100520598","NCT06058650","Molecular Breast Imaging Guidance for Breast Biopsy for Patients With Breast Abnormalities","Pilot Clinical Study to Evaluate Molecular Breast Imaging- Guidance for Sampling of Breast Abnormalities","Inclusion Criteria:\n\n* PART I: Women aged 18 years or older\n* PART I: If able to become pregnant, negative pregnancy test within 48 hours prior to MBI biopsy procedure\n* PART I: Individuals who have previously (within the last 3 years) undergo an MBI study and were found to have at least one breast imaging finding on MBI that was subsequently shown (through additional imaging, biopsy or follow-up) to be benign in nature\n* PART I: Individuals who have agreed to participate in the study and who have signed the study-specific informed consent\n* PART II: Women aged 18 years or older\n* PART II: If able to become pregnant, negative pregnancy test within 48 hours prior to MBI biopsy procedure\n* PART II: Individuals who have previously (within the last 3 years) undergone an MBI study and were found to have at least one breast imaging finding on MBI that was subsequently shown (through additional imaging, biopsy or follow-up) to be benign or probably benign in nature\n* PART II: Individuals who had recent conventional imaging work-up including either x-ray mammography, ultrasound, MBI, or MRI of the breast and are found to have at least one breast imaging finding for which biopsy is required or recommended, specifically:\n\n  * Individuals who have a breast abnormality(ies) on imaging with mammography, ultrasound, MBI, or MRI (as per American College of Radiology \\[ACR\\] Breast Imaging Reporting and Data System \\[BIRADS\\] 3, or higher) and requiring imaging follow-up or biopsy confirmation\n* PART II: Individuals who have agreed to participate in the study and who have signed study-specific informed consent\n\nExclusion Criteria:\n\n* PART I: Women who are pregnant\n* PART I: Women who are currently lactating or discontinued breastfeeding \\\u003C 2 months prior to the study\n* PART I: Age less than 18 years\n* PART I: Women with breast implant(s) in the breast containing the lesion of interest\n* PART I: Inability to provide informed consent\n* PART II: Women who are pregnant\n* PART II: Women who are currently lactating or discontinued breastfeeding \\\u003C 2 months prior to the study\n* PART II: Age less than 18 years\n* PART II: Women with breast implant(s) in the breast containing the lesion of interest\n* PART II: Women who have recently (within the last 3 months) undergone biopsy of the breast finding\n* PART II: Women who are scheduled for a sentinel node procedure using radioactive Tc-99m within 24 hours of MBI-guided biopsy\n* PART II: Patients with contraindications for core biopsy and other invasive procedures such as blood coagulation disorders, infection, or who are unwilling to discontinue use of anticoagulant medication prior to the procedure\n* PART II: Inability to provide informed consent\n* PART II: Women who have had surgery on the study breast(s) within the past 12 months",{"count":346,"type":21},70,[24],"This clinical trial tests how well molecular breast imaging (MBI) works to guide the collection of a breast biopsy in patients with a breast abnormality. Currently, a biopsy is often guided by either ultrasound or mammography in order to ensure that a sample of the correct part of the breast is taken. Sometimes a lesion or part of the lesion cannot be seen on ultrasound or mammography, and, therefore, a biopsy guided with ultrasound or mammography may not be always be accurate. Studies have shown that high resolution MBI may have potential to improve the detection of some breast tumors. This trial uses a new high-resolution MBI system that may help perform a biopsy using MBI.",[28],"2025-09-29",{"date":352,"type":52},"2025-09-30",{"date":354,"type":52},"2021-08-26",{"date":356,"type":21},"2026-08-26",{"name":230,"class":59},{"id":359,"slug":360,"hasResults":11,"nctId":361,"briefTitle":362,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":364,"enrollmentInfo":365,"targetDuration":4,"studyType":22,"phases":367,"briefSummary":368,"conditions":369,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":376,"locationsCount":60},"100538725","improved-successful-retrieval-rate-of-hydromark-plus-breast-biopsy-site-marker-in-comparison-to-hydromark-as-well-as-improved-surgeon-satisfaction-100538725","NCT06294574","Improved Successful Retrieval Rate of HydroMARK Plus Breast Biopsy Site Marker in Comparison to HydroMARK as Well as Improved Surgeon Satisfaction","Inclusion Criteria:\n\n* Patients with biopsy clips scheduled for surgery with SCOUT localization\n\nExclusion Criteria:\n\n* Patients who didn't have surgery, patients younger than 18 years old\n* Patients older than 90 years old\n* Inmates\n* Non-English speakers","90 Years",{"count":366,"type":21},150,[24],"The purpose of the study is to test how successful the retrieval rate of the new HydroMARK Plus Breast Biopsy Site Marker in comparison to HydroMARK.",[28],"2025-09-17",{"date":372,"type":52},"2025-09-22",{"date":374,"type":52},"2025-08-05",{"date":181,"type":21},{"name":377,"class":59},"University of Alabama at Birmingham",{"id":379,"slug":380,"hasResults":11,"nctId":381,"briefTitle":382,"officialTitle":382,"acronym":4,"eligibilityCriteria":383,"healthyVolunteers":11,"sex":17,"minAge":192,"maxAge":4,"enrollmentInfo":384,"targetDuration":4,"studyType":22,"phases":386,"briefSummary":387,"conditions":388,"keywords":391,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":395,"startDateStruct":397,"completionDateStruct":399,"leadSponsor":401,"locationsCount":404},"100191324","phase-2-phase-ii-protocol-of-proton-therapy-for-partial-breast-irradiation-in-early-stage-breast-cancer-100191324","NCT01766297","Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer","Inclusion Criteria:\n\n* Must sign study-specific, IRB approved informed consent form prior to study entry. Note consent by legally authorized representative is not allowed for this trial.\n* Must be female.\n* Must be \\> = 50 years of age.\n* Must have a life expectancy of at least 5 years based on age and co-morbidities.\n* Must have pathology proven invasive ductal carcinoma (lobular is not allowed) and\u002For ductal carcinoma in situ (DCIS).\n* One of the following criteria must be met: (a) Tumors that are microscopically multifocal must be 3.0 cm or less in total aggregate size and encompassed within a single scar (b) Patient does not have microscopically multifocal tumor.\n* For tumors that are invasive, if in the presence of extensive intraductal component (EIC), the entire pathologic tumor size (including both the intraductal and invasive component) must be 3.0 cm or less.\n* Must be Stage 0, I, II (Tis, T1, or T2, N0, M0 per AJCC criteria 7th and\u002For 8th Ed.). If stage II, the tumor size must be \\\u003C = 3.0 cm. A patient with invasive histology must have nodal stage pN0 by H\\&E stains on sentinel node biopsy or axillary lymph node dissection.\n* Must have ER positive disease with ER\u002FPR report available.\n* For tumors that are invasive, HER2 must be performed (positive or negative is acceptable).\n* Must have a lumpectomy performed, with documented negative surgical margins by 0.2 cm or more. If re-excision results in negative surgical margins 0.2 cm or more, patient is eligible.\n* If image guidance with daily cone beam CT with direct physician visual assessment is used for treatment positioning, the presence of markers or clips in the surgical bed is recommended but not required. If cone beam CT imaging will NOT be used for image guidance, then the patient must be prepared to have 2 fiducial markers minimum, 3 preferred, placed prior to treatment (if not previously done).\n\n  * If markers or clips were placed at the time of surgery, patient must be able to start treatment within 12 weeks after lumpectomy or re-excision for adequate margins.\n  * If markers were not placed at the time of surgery and are needed, patient must have markers placed within 6 weeks after surgery.\n  * If systemic chemotherapy was given, patient must have had clips or markers placed at the time of surgery (if they are needed) and patient must have simulation scans within 6 weeks of the completion of the chemotherapy.\n* Must be able to start treatment within 12 weeks of surgery or 8 weeks of finalization of chemotherapy.\n\nExclusion Criteria:\n\n* Previous history of ipsilateral invasive breast cancer or DCIS.\n* Any clinical or radiographically suspicious nodes, unless biopsy proven benign.\n* Non-epithelial malignancies such as sarcoma or lymphoma.\n* Suspicious residual microcalcifications on mammography of either breast, unless negative for malignancy on pathology.\n* Multicentric or bilateral disease unless biopsy of the clinical abnormalities are performed and result is negative.\n* Lymphovascular space invasion (LVSI) on pathology specimen.\n* Any previously treated breast carcinoma or synchronous breast carcinoma in ipsilateral breast.\n* Prior radiation therapy to the ipsilateral breast or thorax.\n* Paget's disease of the nipple.\n* Histologic examination showing invasive lobular histology.\n* Skin involvement.\n* Breasts technically unsatisfactory for radiation treatment upon the discretion of the treating physician.\n* Significant infection or other co-existing medical condition that would preclude protocol therapy such as pregnancy, HIV\u002FAIDS or collagen vascular diseases specifically systemic lupus erythematosus, scleroderma, or dermatomyositis.\n* Known BRCA 1 or BRCA 2 mutation.\n* Pregnant or lactating.",{"count":385,"type":21},132,[73],"The purpose of this research study is to compare the effects (good and bad) on women and their cancer using proton radiation therapy.\n\nThis study is being done to see if proton radiation therapy will prove to be beneficial for women with early stage breast cancer. A clinical study is necessary to compare the results (good or bad) of proton radiation therapy.",[27,28,389,390],"Breast Tumor","Cancer of the Breast",[27,392,393],"Proton","Radiation","2025-09-02",{"date":396,"type":52},"2025-09-09",{"date":398,"type":4},"2013-02",{"date":400,"type":21},"2035-01",{"name":402,"class":403},"Proton Collaborative Group","NETWORK",9,{"id":406,"slug":407,"hasResults":11,"nctId":408,"briefTitle":409,"officialTitle":409,"acronym":410,"eligibilityCriteria":411,"healthyVolunteers":11,"sex":101,"minAge":18,"maxAge":4,"enrollmentInfo":412,"targetDuration":4,"studyType":22,"phases":414,"briefSummary":415,"conditions":416,"keywords":419,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":432,"locationsCount":434},"100342612","phase-2-phoenix-ddranti-pd-l1-trial-a-pre-surgical-window-of-opportunity-and-post-surgical-adjuvant-biomarker-study-of-dna-damage-response-inhibition-with-or-without-anti-pd-l1-immunotherapy-in-patients-with-neoadjuvant-treatment-resistant-residual-triple-negative-breast-cancer-100342612","NCT03740893","PHOENIX DDR\u002FAnti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer","PHOENIX","Inclusion Criteria for Trial Registration:\n\n1. Signed Informed Consent Form (ICF) for Trial Registration;\n2. Aged ≥18 years old;\n3. Histologically confirmed invasive triple negative breast cancer (TNBC). TNBC defined as ER negative, PgR negative (ER and PgR negative as defined by Allred score 0\u002F8, 1\u002F8 or 2\u002F8 or stain in \\\u003C1% of cancer cells) or PgR unavailable, and HER2 negative (immunohistochemistry 0\u002F1+ or negative in situ hybridization) as determined by local laboratory and recorded in the patients notes;\n4. Planned definitive surgical treatment after at least 6 cycles of neoadjuvant chemotherapy (NACT) Patients currently receiving SOC pembrolizumab, or having previously received SOC pembrolizumab but subsequently discontinued treatment, in combination with NACT are eligible for Trial Registration;\n5. Radiographically measurable tumour mass assessable for new distinct radio-opaque marker insertion and repeated biopsies on the NACT mid-assessment standard of care imaging modality;\n6. Eastern Oncology Cooperative Group (ECOG) performance status 0-1;\n7. Considered fit enough to have breast cancer surgery with curative intent;\n8. Considered fit to complete at least 2 weeks of pre-operative trial treatment in the WOP;\n9. Patients must be suitable for a mandatory pre-treatment baseline biopsy performed Day -1 or 1 of the window of opportunity (WOP) and a post-treatment biopsy performed on Day 14 of the WOP. Registered patients who are approached for Trial Entry will be required to consent to the pre- and post- WOP treatment biopsy. If it is deemed unsafe to proceed with biopsy upon Trial Entry the patient will not be eligible for participation in the trial.\n10. Patients with clinical stage II or III disease or clinical suspicion of metastatic disease must have staging studies to exclude metastatic disease if this is standard of care, and staging methods should be used as per standard of care (axillary lymph nodes or internal mammary node involvement will not be regarded as evidence of metastatic disease);\n11. Patients with previous invasive cancers (including breast cancer) are eligible if the treatment was completed \\>5 years prior to Trial Registration, and there is no evidence of recurrent disease;\n12. Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the trial protocol and follow-up schedule; those conditions should be discussed with the patient before Trial Registration;\n13. Patients must be a) surgically sterile (i.e. if female have undergone a hysterectomy, bilateral salpingectomy or bilateral oophorectomy; if male have undergone a bilateral orchidectomy); b) have a sterilised sole partner; or c) be post-menopausal; or d) must agree to practice total\u002Ftrue abstinence; or e) use a condom and one highly effective form of contraception in combination during the period of trial treatment and be willing to do so for a period of at least 6 months following the end of trial treatment. Please refer to Section 5.4 Lifestyle Guidance for the definition of total\u002Ftrue abstinence and a list of the permitted highly effective forms of contraception.\n\nPost-menopausal is defined by at least one of the following criteria:\n\n1. Amenorrhoeic for 1 year or more following cessation of exogenous hormonal treatments\n2. Luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels in the post-menopausal range for the institution for women \\\u003C 50 years of age not using hormonal contraception or hormonal replacement therapy. Please note: in absence of amenorrhea for 1 year, a single LH and\u002For FSH measurement is insufficient.\n3. Radiation-induced oophorectomy with last menses \\>1 year ago\n4. Chemotherapy-induced menopause with \\>1 year interval since last menses\n5. Surgical sterilisation (hysterectomy, bilateral salpingectomy or bilateral oophorectomy)\n\nExclusion Criteria for Trial Registration:\n\n1. Definitive evidence of metastatic disease (axillary lymph nodes or internal mammary node involvement will not be regarded as evidence of metastatic disease) ;\n2. Patients with bilateral tumours.\n3. History of another primary malignancy within the last 5 years prior to Trial Registration, except for:\n\n   1. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease;\n   2. Adequately treated carcinoma in situ without evidence of disease;\n4. Patients with myelodysplastic syndrome (MDS)\u002Facute myeloid leukaemia (AML) or with features suggestive of MDS\u002FAML;\n5. Severe concurrent disease, infection or co-morbidity that, in the judgment of the local Investigator, would make the patient inappropriate for Trial Registration;\n6. Resting ECG indicating uncontrolled, potentially irreversible cardiac conditions, as judged by the investigator (e.g., unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, QTcF prolongation \\>470 msec, electrolyte disturbances, etc.), or patients with congenital long QT syndrome;\n7. Patients unable to swallow orally administered medication;\n8. Patients receiving therapeutic anti-coagulation treatment (including warfarin and novel oral anti-coagulants).\n9. Patients with gastrointestinal disorder affecting absorption (e.g. gastrectomy, active peptic ulcer disease within last 3 months);\n10. History of seizure or any condition that may predispose to seizure.\n11. Other non-malignant systemic disease that would preclude trial treatment or would prevent required follow-up;\n12. Pregnant or breast-feeding;\n13. Prior exposure to PARP inhibitor, including olaparib, anti-PD-1 or anti-PDL1 immunotherapy (including durvalumab) except for pembrolizumab if received as standard of care in combination with neoadjuvant chemotherapy;\n14. Any other disease(s), psychiatric condition, metabolic dysfunction, or findings from a physical examination or clinical laboratory test result that in the investigators opinion would cause reasonable suspicion of a disease or condition, that contraindicates the use of trial treatment, that may increase the risk associated with trial participation, that may affect the interpretation of the results, or that would make this trial inappropriate for the patient;\n15. Patients with a known hypersensitivity to pembrolizumab, durvalumab or olaparib or any excipients of the products;\n16. Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT);\n17. Active infection including tuberculosis (TB) (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (HBV; known positive HBV surface antigen (HBsAg) result), hepatitis C (HCV), or human immunodeficiency virus (HIV; positive HIV 1\u002F2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \\[anti-HBc\\] and absence of HBsAg) are eligible. Patients positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA;\n\nInclusion Criteria for Trial Entry:\n\n1. Signed Informed Consent Form (ICF) for Trial Entry;\n2. Residual disease is confirmed as at least one viable disease focus ≥1cm on trial-specific imaging performed at least 1 week following day 1 of the final cycle of NACT.\n3. Provision of acceptable archival diagnostic tumour tissue sample prior to Trial Entry as defined in the Investigator Laboratory Manual.\n4. Recovery from all acute adverse events of prior NACT or pembrolizumab to baseline or NCI CTCAE Grade ≤1, except for alopecia. Patients with irreversible toxicity not reasonably expected to be exacerbated by trial treatment may be included only after consultation with the CI or Coordinating Investigator.\n5. Patients must have adequate haematological, renal and hepatic function as defined by:\n\n   * Haemoglobin (Hb) ≥ 10 g\u002FdL (≥ 100 g\u002FL) with no blood transfusion in the past 28 days\n   * Absolute neutrophil count (ANC) ≥ 1500\u002Fmm3 (≥ 1.5 x 109\u002FL)\n   * Platelet count ≥100,000\u002Fmm3 (≥ 100 x 109\u002FL)\n   * Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN)\n   * Aspartate aminotransferase (AST) (Serum Glutamic Oxaloacetic Transaminase (SGOT)) \u002F Alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase (SGPT)) ≤ 2.5 x institutional ULN\n   * Calculated creatinine clearance ≥51 mL\u002Fmin using the Cockcroft-Gault equation (please refer to Appendix 4) or based on a 24 hour urine test or another validated test as per local practice\n6. Women of childbearing potential must have a confirmed menstrual period and a negative urinary or serum pregnancy test prior to Trial Entry. This should be repeated as applicable to ensure a negative pregnancy test is performed on the day of planned trial treatment.\n7. Confirmation that all Trial Registration inclusion criteria listed in Section 5.3.1 remain satisfied.\n\nExclusion Criteria for Trial Entry:\n\n1. Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on High Resolution Computed Tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining informed consent.\n2. Major surgery (excluding minor procedures, e.g. placement of vascular access) within 2 weeks prior to Trial Entry. Patients must have recovered from any effects of any major surgery prior to commencing trial treatment.\n3. Use of any investigational agent within 30 days prior to commencing trial treatment.\n4. Concomitant use of known strong CYP3A inhibitors (e.g. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (e.g. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to commencing trial treatment is 5 weeks;\n5. Concomitant use of known strong (e.g. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or moderate (e.g. bosentan, efavirenz, modafinil) CYP3A inducers. The required washout period prior to commencing trial treatment is 5 weeks;\n6. Whole blood infusion within 28 days prior to trial entry (packed red blood cells and platelet transfusions are acceptable).\n7. Receipt of live attenuated vaccine within 30 days prior to commencing trial treatment.\n8. Confirmation that none of the Trial Registration exclusion criteria listed in Section 5.3.2 are met.",{"count":413,"type":21},119,[73],"PHOENIX is a window of opportunity (WOP), open-label, multi-centre, phase IIa trial comprising multiple non-comparative treatment cohorts with patient allocation via minimisation (cohorts A-D) or allocation according to HRD and germline BRCA1\u002F2 mutation status (cohorts E-G). The trial consists of two parts: a post-neoadjuvant treatment preoperative WOP component (PART 1); and a post-operative component (PART 2).\n\nCohorts A-D: To assess whether short exposure to a DDR inhibitor or anti-PD-L1 immunotherapy in a preoperative WOP in patients with post-NACT high risk residual disease, generates a signal of anti-tumour biological activity within residual disease tissue.\n\nCohort E: To assess whether short exposure to a DDR inhibitor with or without anti-PD-1 immunotherapy in a preoperative WOP in patients with non-HRD associated TNBC and post-neoadjuvant treatment high risk residual disease, generates a signal of anti-tumour biological activity within residual disease tissue.\n\nCohorts F \\& G: To assess whether short exposure to the DDR inhibitor olaparib with or without anti-PD-1 immunotherapy in a preoperative WOP in patients with HRD associated TNBC and post-neoadjuvant treatment high risk residual disease, generates a signal of anti-tumour biological activity within residual disease tissue.",[28,417,418],"Triple Negative Breast Cancer (TNBC)","HRD",[420,421,422,423,424,298,425],"AZD6738","Olaparib","Durvalumab","Window of opportunity","Triple negative breast cancer","Homologous Repair Deficiency (HRD)",{"date":427,"type":52},"2025-08-11",{"date":429,"type":52},"2019-10-15",{"date":431,"type":21},"2029-06",{"name":433,"class":59},"Institute of Cancer Research, United Kingdom",6,{"id":436,"slug":437,"hasResults":11,"nctId":438,"briefTitle":439,"officialTitle":440,"acronym":441,"eligibilityCriteria":442,"healthyVolunteers":11,"sex":17,"minAge":443,"maxAge":4,"enrollmentInfo":444,"targetDuration":4,"studyType":22,"phases":446,"briefSummary":447,"conditions":448,"keywords":453,"overallStatus":463,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":469,"locationsCount":60},"100601760","molecular-breast-imaging-mbi-guided-biopsy-100601760","NCT07114679","Molecular Breast Imaging (MBI)-Guided Biopsy","Molecular Breast Imaging (MBI)-Guided Biopsy Pilot SBIR","MBI-GB-Pilot","Inclusion Criteria:\n\n* dense breasts (BI-RADS C or D) on screening DBT\n\nExclusion Criteria:\n\n* pregnancy","21 Years",{"count":445,"type":21},250,[24],"The goal of this pilot clinical trial is to demonstrate supplemental screening MBI (molecular breast imaging) in women with dense breasts. The main questions it aims to answer are:\n\n* Does screening MBI find more cancer than screening DBT (3D mammography, digital breast tomosynthesis?\n* Does screening MBI result in more call-backs for biopsy than DBT?\n* How well does MBI-guided biopsy conform with pathology reports?\n\nResearchers will compare screening MBI to screening DBT to see if MBI is more sensitive to detecting cancer in women with dense breasts.\n\nParticipants will\n\n* Receive both screening DBT and screening MBI\n* Receive either DBT-guided or MBI-guided biopsy (randomly assigned), if required by the screening images",[449,28,450,451,452],"Breast Cancer Detection","Molecular Imaging","Biopsy","Dense Breasts",[454,455,456,457,458,459,460,461,462],"screening","crossover","single-group","pilot","biopsy","randomized assignment","dense breasts","MBI","molecular imaging","NOT_YET_RECRUITING","2025-08-03",{"date":427,"type":52},{"date":467,"type":21},"2027-06",{"date":123,"type":21},{"name":470,"class":126},"Smart Breast Corp.",{"id":472,"slug":473,"hasResults":11,"nctId":474,"briefTitle":475,"officialTitle":476,"acronym":477,"eligibilityCriteria":478,"healthyVolunteers":11,"sex":101,"minAge":18,"maxAge":4,"enrollmentInfo":479,"targetDuration":4,"studyType":22,"phases":481,"briefSummary":482,"conditions":483,"keywords":484,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":489,"lastUpdatePostDateStruct":490,"startDateStruct":492,"completionDateStruct":494,"leadSponsor":496,"locationsCount":254},"100580569","phase-3-cryoablation-for-small-tumors-as-local-treatment---six-trial-100580569","NCT06839001","CRYoablation for Small Tumors As Local Treatment - SIX Trial","Cryoablation Versus Breast Surgery in the Local Treatment of Early-Stage Breast Cancer - Six Trial","CRYSTAL - SIX","Inclusion Criteria:\n\n* Unifocal primary invasive breast carcinoma\n* Tumor size ≤ 2.0 cm (T1)\n* Complete pathological report (including results for ER, PR, HER2, Ki-67, and FISH report for the ERBB2 gene, if necessary)\n* Lesion visible on ultrasound\n* Surgical treatment would be the first option, regardless of immunohistochemistry results\n\nExclusion Criteria:\n\n* Multifocal or multicentric invasive breast carcinoma\n* Ductal carcinoma in situ\n* Breast cancer with skin involvement\n* Clinically positive axilla (N1, N2 or N3)\n* Distance from lesion and skin less than 5 mm\n* Prior neoadjuvant systemic therapy for breast cancer\n* Distant metastasis",{"count":480,"type":21},750,[105],"To demonstrate the non-inferiority of cryoablation compared to breast surgery for the local treatment of early-stage breast cancer and to conduct a cost-minimization analysis comparing direct costs between treatments.",[27,28],[27,485,486,487,488],"Minimally Invasive Surgical Procedures","Cryoablation","Locoregional Recurrence","Cost-Minimization Analysis","2025-06-23",{"date":491,"type":52},"2025-06-26",{"date":493,"type":52},"2025-03-01",{"date":495,"type":21},"2030-03-01",{"name":497,"class":59},"Hospital do Coracao",{"id":499,"slug":500,"hasResults":11,"nctId":501,"briefTitle":502,"officialTitle":503,"acronym":504,"eligibilityCriteria":505,"healthyVolunteers":11,"sex":101,"minAge":18,"maxAge":4,"enrollmentInfo":506,"targetDuration":4,"studyType":22,"phases":508,"briefSummary":509,"conditions":510,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":254},"100440865","phase-2-correlation-of-clinical-response-to-pathologic-response-in-patients-with-early-breast-cancer-100440865","NCT05020860","Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer","A Phase II Trial to Correlate Early Clinical Response to Pathologic Outcome With Neoadjuvant Systemic Therapy in Patients With Early Stage Breast Cancer","RESPONSE","Inclusion Criteria:\n\n* At least 18 years of age, and legally able to provide informed consent. Both men and women are eligible.\n* Histologically confirmed, invasive breast cancer. Tumor may be triple negative (as defined by ASCO-CAP guidelines), HER2-positive (as defined by ASCO-CAP guidelines), or high-risk estrogen receptor positive (as defined by ASCO-CAP guidelines).\n\nTo be considered \"high risk,\" at least 2 of the following criteria must be met: 1) histologic grade 3; 2) patient age 50 or less; 3) ER Allred score \\\u003C 6; 4) Ki-67 ≥ 30%.\n\n* Tumors must be at least 2 cm by clinical exam or ultrasound\n* Bilateral breast cancers are allowed if the following criteria are met: 1) A lesion on one side (meeting the criteria above) is designated as the index lesion on which study assessments will be performed, and 2) the same treatment regimen is appropriate for both cancers as determined by the treating physician.\n* ECOG performance status of 0 or 1\n* Left ventricular ejection fraction (LVEF) ≥ the institutional lower limit of normal, as assessed by echocardiogram or Multigated Acquisition (MUGA )scan.\n* Adequate organ function, as determined by the following parameters:\n\n  * Absolute Neutrophil Count (ANC) ≥ 1200\u002Fmm3\n  * Platelets ≥ 100,000\u002Fmm3\n  * Hemoglobin ≥ 9 g\u002FdL\n  * Total bilirubin ≤ institutional upper limit of normal (ULN), unless patient has Gilbert's disease or similar syndrome\n  * Alkaline phosphatase (ALP) ≤ 2.5 x institutional ULN\n  * Aspartate aminotransferase (AST)\u002Falanine aminotransferase (ALT) ≤ 1.5 x institutional ULN\n  * Serum creatinine ≤ institutional ULN\n* The participant, if of childbearing potential, is willing to use effective, non-hormonal contraception while on treatment.\n* Participation in a concurrent clinical trial is permitted, with Principal Investigator approval.\n\nExclusion Criteria:\n\n* Definitive clinical or radiologic evidence of Stage IV disease\n* Inflammatory breast cancer\n* Participants who are pregnant or lactating\n* History of an excisional biopsy or lumpectomy performed prior to study entry\n* Prior treatment with anthracyclines for any malignancy.\n* Prior treatment for currently diagnosed breast cancer (i.e., endocrine therapy, chemotherapy, targeted therapy, or radiation.\n* History of cardiac disease that would preclude the use of drugs included in these treatment regimens. This includes, but is not limited to:\n\n  * Angina pectoris requiring the use of anti-anginal medication\n  * Ventricular arrhythmias except for benign premature ventricular contractions\n  * Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication\n  * Conduction abnormality requiring a pacemaker\n  * Valvular disease with documented compromise in cardiac function\n  * Symptomatic pericarditis\n  * Documented cardiomyopathy\n  * History of documented congestive heart failure (CHF)\n  * Myocardial infarction documented by elevated cardiac enzymes, or persistent regional wall abnormalities on assessment of left ventricular function.\n* Current HIV, hepatitis B, or hepatitis C infection\n* History of non-breast malignancies (with the exception of in situ cancers treated only by local excision, and basal cell or squamous cell carcinoma of the skin) within 5 years prior to enrollment.\n* Any other non-malignant systemic disease that would preclude treatment with any of the treatment regimens or prevent required follow-up.\n* Any psychiatric or addictive disorders, adverse social situations, or other medical conditions that, in the opinion of the investigator, would preclude the patient from meeting study requirements.",{"count":507,"type":21},185,[73],"The purpose of this study is to learn whether clinical response (the amount a tumor shrinks based on imaging or tumor measurements obtained by physical exam) predicts pathologic response (the amount of tumor remaining when surgery is performed) in participants with breast cancer who are receiving chemotherapy prior to surgery.",[27,28,511,158,141,142,512,513,78,514,515],"Breast Cancer Female","Triple Negative Breast Cancer","Hormone Receptor-positive Breast Cancer","Triple Negative Breast Neoplasms","Estrogen Receptor-positive Breast Cancer","2025-02-25",{"date":518,"type":52},"2025-02-27",{"date":520,"type":52},"2023-04-18",{"date":522,"type":21},"2029-11",{"name":524,"class":59},"Baylor Breast Care Center",{"id":526,"slug":527,"hasResults":11,"nctId":528,"briefTitle":529,"officialTitle":530,"acronym":531,"eligibilityCriteria":532,"healthyVolunteers":11,"sex":101,"minAge":18,"maxAge":4,"enrollmentInfo":533,"targetDuration":4,"studyType":219,"phases":4,"briefSummary":535,"conditions":536,"keywords":572,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":578,"startDateStruct":580,"completionDateStruct":582,"leadSponsor":584,"locationsCount":5},"100578016","predicting-clinical-outcomes-during-first-line-cdk46-inhibitors-plus-endocrine-therapy-in-patients-with-advanced-hormone-receptor-positive-her2-negative-breast-cancer-the-retrospective-prospective-multicenter-italian-palmares-2-study-100578016","NCT06805812","Predicting clinicAL outcoMes During First-line CDK4\u002F6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study","Predictive Impact of Peripheral Blood Lymphocytes on clinicAL outcoMes During First-line CDK4\u002F6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study","PALMARES-2","Inclusion Criteria:\n\n* Diagnosis of HR+\u002FHER2- advanced Breast Cancer (aBC), as defined as at least 1% estrogen receptor (ER) and\u002For progesterone receptor (PgR) positivity at IHC. HER2 negativity is defined on the basis of an IHC score of 0, 1+, or 2+ with absence of gene amplification at in situ hybridization (ISH) analyses.\n* Have received or are candidate to receive treatment with palbociclib, ribociclib or abemaciclib in combination with endocrine therapy as first-line treatment for HR+\u002FHER2- aBC.\n\nExclusion Criteria:\n\n* Less than 3 months of follow up from the CDK4\u002F6i start to the date of data cut-off;\n* Have received CDK4\u002F6i as monotherapy;\n* Have received CDK4\u002F6i as adjuvant treatment for localized disease.",{"count":534,"type":21},3500,"PALMARES-2 is a retrospective\u002Fprospective, observational, multicenter, population-based study, aiming at providing real-world evidences on HR+\u002FHER2- aBC patients treated with first-line CDK4\u002F6i plus ET. The present study has the objective to collect data coming from different sources, i.e. RWD, medical images and biological samples, from patients treated with CDK4\u002F6i as first-line of therapy for HR+\u002FHER2- aBC. In consideration of the complexity of data collected and different objectives of the study, this master protocol foresees different sub-studies, which encompasses different methodologies for data collection, data extraction and analyses.",[537,143,538,169,539,272,540,27,541,542,28,76,543,544,545,546,547,548,549,550,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567,568,569,570,571],"Breast Adenocarcinoma","Breast Cancer, Metastatic","Breast Diseases","Breast Neoplasms, Male","Breast Cancer With Metastatic Bone Disease","Breast Cancers","HR+ HER2- Men, Pre\u002FPostmenopausal Advanced Breast Cancer","HR+ Advanced or Metastatic Breast Cancer","HR+\u002FHER2- Breast Cancer","HRpos Breast Neoplasms","HR-positive, HER2-negative Advanced Breast Cancer","HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer","HR-positive Breast Cancer","Hormone Receptor-Positive Breast Cancer","Hormone Receptor Positive Breast Adenocarcinoma","Hormone Receptor Positive Breast Carcinoma","Hormone Receptor Positive Breast Neoplasms","Hormone Receptor Positive HER-2 Negative Breast Cancer","Hormone Receptor Positive Malignant Neoplasm of Breast","Hormone Receptor Positive Metastatic Breast Cancer","Hormone Receptor Positive, HER2 Negative Breast Cancer","Hormone Receptor Negative Breast Cancer","Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer","Hormone Receptor Positive Breast Cancer","Hormone Receptor Positive (ER+\u002FPR+, and Her2-) Metastatic Breast Cancer","Hormone Receptor Positive, HER2-negative Neoplasms","Hormone Receptor Positive, HER2-low Neoplasms","Hormone Receptor Positive (HR+), HER2-negative Breast Cancer","Hormone Receptor (HR)-Positive Breast Cancer","Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer","Palbociclib","Ribociclib","Abemaciclib","CDK4\u002F6 Inhibitor","CDK4\u002F6 Inhibitors",[573,574,567,568,569,575,576,108],"HR+\u002FHER2- Advanced Breast Cancer","HR+\u002FHER2- Metastatic Breast Cancer","CDK4\u002F6i","Cyclin-Dependent Kinase 4\u002F6 inhibitors","2025-01-28",{"date":579,"type":52},"2025-02-03",{"date":581,"type":52},"2023-05-01",{"date":583,"type":21},"2040-12-31",{"name":585,"class":59},"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",{"id":587,"slug":588,"hasResults":11,"nctId":589,"briefTitle":590,"officialTitle":591,"acronym":4,"eligibilityCriteria":592,"healthyVolunteers":11,"sex":101,"minAge":443,"maxAge":4,"enrollmentInfo":593,"targetDuration":4,"studyType":22,"phases":595,"briefSummary":597,"conditions":598,"keywords":599,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":602,"lastUpdatePostDateStruct":603,"startDateStruct":605,"completionDateStruct":607,"leadSponsor":609,"locationsCount":611},"100521916","phase-1-a-study-of-oral-mbq-167-in-participants-with-advanced-breast-cancer-100521916","NCT06075810","A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer","A Phase 1 Open-Label, First-in-Human Trial of Oral MBQ-167 as Single Agent in Participants With Advanced Breast Cancer","Key Inclusion Criteria:\n\n* The investigator will evaluate these and other criteria to determine whether a participant can be included in this study.\n* Histologically and\u002For cytologically confirmed advanced breast cancer which has progressed after treatment with approved therapies or for which there are no standard therapies available.\n* Participants with known brain metastases may be eligible if specific conditions are met.\n* Life expectancy ≥6 months, in the opinion of the investigator, after starting MBQ-167.\n* Are able to swallow capsules twice daily with a meal.\n\nKey Exclusion Criteria:\n\n* The investigator will evaluate these and other criteria to determine whether a participant should be excluded from this study.\n* Inability to take oral medication, or malabsorption syndrome or any other uncontrolled gastrointestinal condition (e.g., nausea, diarrhea, or vomiting) that might impair the bioavailability of MBQ-167.\n* Females who are pregnant or breastfeeding.\n* Participants who have received any anticancer treatment within 4 weeks or any investigational agent within 28 days prior to the first dose of trial drug or who have not recovered from any acute toxicity greater than Grade 0 or 1 related to previous anticancer treatment.\n* Participants who have received any anticancer treatment within 4 weeks or any investigational agent within 28 days prior to the first dose of trial drug or who have not recovered from any acute toxicity greater than Grade 0 or 1 related to previous anticancer treatment.\n* Active malignancies other than advanced breast cancer will be excluded from the study.",{"count":594,"type":21},48,[596],"PHASE1","A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of Care (SOC) has failed or has proven intolerable.",[27,28,143],[600,108,601],"Advanced Breast Cancer","Recurrent Breast Cancer","2024-12-09",{"date":604,"type":52},"2024-12-12",{"date":606,"type":52},"2023-11-09",{"date":608,"type":21},"2025-10-31",{"name":610,"class":126},"MBQ Pharma",4,{"id":613,"slug":614,"hasResults":11,"nctId":615,"briefTitle":616,"officialTitle":617,"acronym":618,"eligibilityCriteria":619,"healthyVolunteers":11,"sex":101,"minAge":18,"maxAge":4,"enrollmentInfo":620,"targetDuration":4,"studyType":22,"phases":622,"briefSummary":623,"conditions":624,"keywords":628,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":651,"lastUpdatePostDateStruct":652,"startDateStruct":654,"completionDateStruct":656,"leadSponsor":658,"locationsCount":254},"100564575","evaluating-the-impact-of-financial-navigation-on-financial-catastrophe-and-distress-for-cancer-care-100564575","NCT06630962","Evaluating the Impact of Financial Navigation on Financial Catastrophe and Distress for Cancer Care","Evaluating the Impact of Financial Navigation on Financial Catastrophe and Distress for Cancer Care: A Randomized Control Trial- COST-FIN","COST-FIN","Inclusion Criteria:\n\n* Age 18 years and older\n* Recently diagnosed with breast, colorectal or prostate cancer within 6 weeks of presentation at the study site\n* Have not received definitive chemotherapy, radiotherapy, or undergone major surgery (diagnostic or temporary interventions, such as excisional biopsy or temporary colostomy may still enroll)\n* Candidate for definitive cancer treatment\n\nExclusion Criteria:\n\n* Unable to provide consent\n* Has initiated definitive cancer treatment at the study site or elsewhere in the past\n* Only receiving best supportive care",{"count":621,"type":21},200,[24],"The goal of this study is to investigate the effectiveness of a structured financial navigation program in reducing financial catastrophe and financial distress for cancer patients in Nigeria.\n\nThe main study questions being investigated are:\n\n1. If a financial navigation program can effectively and significantly reduce financial catastrophe and distress for cancer patients in Nigeria?\n2. If a financial navigation program is financially sustainable and cost-effective for cancer centers in Nigeria?\n\nParticipants will be required to:\n\n1. Complete surveys about their demographics, clinical history, and socioeconomic status\n2. Complete questionnaires about their quality of life and psychological wellbeing\n3. Report all costs related to their cancer care\n\nInvestigators will compare participants in the financial navigation program and those not in the financial navigation program to identify potential differences in catastrophic health expenditure and financial distress.",[28,625,626,627],"Prostate Neoplasm","Colon Neoplasm","Rectal Neoplasm",[629,630,631,28,625,626,627,632,633,634,635,636,637,638,639,640,641,642,643,644,645,646,647,648,649,650],"Financial Navigation","Financing Cancer Care","Nigeria","Health Insurance","Randomized Control Trial","Healthcare Cost","Health Expenditure","Financial Risk Sharing","Universal Health Insurance","National Health Insurance Scheme","Catastrophic Health Spending","Financial Distress","Sub-Saharan Africa","Health Plan Implementation","Global Health","Healthcare Economics and Organizations","Clinical Oncology","Cancer Care Facilities","Surgical Oncology","Global Burden of Disease","Social Determinants of Health","Health Impact Assessment","2024-10-04",{"date":653,"type":52},"2024-10-08",{"date":655,"type":52},"2024-07-15",{"date":657,"type":21},"2026-09",{"name":659,"class":59},"Northwestern University",{"id":661,"slug":662,"hasResults":11,"nctId":663,"briefTitle":664,"officialTitle":665,"acronym":4,"eligibilityCriteria":666,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":667,"targetDuration":4,"studyType":22,"phases":669,"briefSummary":670,"conditions":671,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":672,"lastUpdatePostDateStruct":673,"startDateStruct":674,"completionDateStruct":676,"leadSponsor":678,"locationsCount":60},"100484902","phase-2-snf-platform-study-of-hr-her2-advanced-breast-cancer-100484902","NCT05594095","SNF Platform Study of HR+\u002F HER2-advanced Breast Cancer","Precision Platform Study of HR+\u002F HER2-advanced Breast Cancer Based on SNF Typing (A Prospective, Open-label, Multi-center, Phase II Platform Study)","Inclusion Criteria:\n\n1. Female aged ≥18 years;\n2. HR+\u002FHER2- invasive breast cancer confirmed by histology (specific definition: ER \\>10% positive tumor cells by immunohistochemistry is defined as ER positive, PR \\>10% positive tumor cells is defined as PR positive, ER and\u002For PR positive is defined as HR positive; HER2 0-1+ or HER2 + but negative by FISH without amplification was defined as HER2 negative);\n3. Locally advanced breast cancer (unable to undergo radical local treatment) or recurrent metastatic breast cancer;\n4. HR+\u002FHER2- advanced breast cancer patients who had previously received CDK4\u002F6 inhibitor therapy;\n5. At least one measurable lesion according to RECIST 1.1 (conventional CT scan ≥20 mm, spiral CT scan ≥10 mm, measurable lesion has not received radiotherapy);\n6. The functions of the main organs are basically normal and meet the following conditions:\n\n   I. Blood routine examination criteria shall meet: HB ≥90 g\u002FL (no blood transfusion within 14 days); The ANC acuity 1.5 x 109 \u002F L; PLT acuity 75 x 109 \u002F L; Ii. Biochemical tests should meet the following criteria: TBIL ≤1.5×ULN (upper limit of normal value); ALT and AST ≤3×ULN; If liver metastases were present, ALT and AST≤ 5×ULN; Serum Cr ≤1×ULN, endogenous creatinine clearance \\> 50 ml\u002Fmin (Cockcroft-Gault formula);\n7. They have not received radiotherapy, molecular targeted therapy, or surgery within 3 weeks before the start of the study, and have recovered from the acute toxicity of previous treatment (if surgery was performed, the wound has healed completely); No peripheral neuropathy or grade I peripheral neurotoxicity;\n8. ECOG score ≤2, and life expectancy ≥3 months;\n9. Fertile female subjects were required to use a medically approved contraceptive method during the study treatment period and for at least 3 months after the last use of the study drug;\n10. Subjects volunteered to join the study, signed informed consent, had good compliance, and cooperated with follow-up.\n\nExclusion Criteria:\n\n1. Radiotherapy (except for palliative causes), chemotherapy, and immunotherapy were used in the first 3 weeks of treatment, except bisphosphonate (which can be used for bone metastasis);\n2. Uncontrolled central nervous system metastases (indicating symptomatic or symptomatic treatment with glucocorticoids or mannitol);\n3. A history of clinically important or uncontrolled heart disease, including congestive heart failure, angina pectoris, myocardial infarction, or ventricular arrhythmia within the last 6 months;\n4. Persistent grade 1 or higher adverse reactions caused by previous treatments. The exception to this is hair loss or something the researchers don't think should be ruled out. Such cases should be clearly documented in the investigator's notes;\n5. Underwent major surgery (except minor outpatient procedures, such as placement of vascular access) within 3 weeks of the first course of trial treatment;\n6. Pregnant or lactating patients; Malignancy (except basal cell carcinoma of the skin, which has been cured, and carcinoma in situ of the cervix) in the past 5 years.",{"count":668,"type":21},620,[73],"The purpose of this study is to establish a prospective, multi-center platform research based on clinical subtypes to explore precision therapy in patients hormone-receptor-positive HER2-negative advanced breast cancer who had previously used CDK4\u002F6 inhibitors.",[28,27,80,79,600],"2024-10-02",{"date":651,"type":52},{"date":675,"type":52},"2022-12-30",{"date":677,"type":21},"2026-12-01",{"name":92,"class":59},{"id":680,"slug":681,"hasResults":11,"nctId":682,"briefTitle":683,"officialTitle":684,"acronym":4,"eligibilityCriteria":685,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":238,"enrollmentInfo":686,"targetDuration":4,"studyType":22,"phases":688,"briefSummary":689,"conditions":690,"keywords":691,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":695,"lastUpdatePostDateStruct":696,"startDateStruct":698,"completionDateStruct":700,"leadSponsor":702,"locationsCount":60},"100523063","improving-lifestyle-behavior-by-joven-fuerte-y-saludable-multidisciplinary-program-100523063","NCT06090747","Improving Lifestyle Behavior by \"Joven, Fuerte y Saludable\" Multidisciplinary Program.","Efecto de Una intervención Multidisciplinaria de Estilo de Vida Sobre el Exposoma de Pacientes premenopáusicas Con cáncer de Mama Estadios I-III.","Inclusion Criteria:\n\n* Women diagnosed with stage I-III BC, confirmed by pathology and image at the INCAN\n* Candidates for multidisciplinary treatment including surgery, chemotherapy, and\u002For hormonal treatments.\n* Signed the informed consent form\n* Have access to a mobile phone or any electronic device with an active internet connection to receive the program information.\n\nExclusion Criteria:\n\n* Patients with inflammatory cancer\n* Those with cardiomyopathy or ventricular dysfunction (NYHA \\>II), arrythmia secondary to left ventricular ejection alterations that requires medication, previous myocardial infarction, or angina pectoris in the last six months\n* Receiving treatment for cardiovascular or cerebrovascular disease, inflammatory bowel disease, malabsorption syndrome, rheumatoid arthritis, lupus, thyroid diseases, or Cushing syndrome\n* Unable to walk for at least 1 km\n* Have cardiovascular, respiratory, or musculoskeletal diseases that impede physical activity\n* Pregnant or breastfeeding\n* Have psychiatric conditions impeding active participation in this protocol\n* Do not understand Spanish",{"count":687,"type":21},146,[24],"Breast cancer is the leading cause of mortality in women worldwide. Latin-American women are diagnosed at younger ages, in advanced stages, and with aggressive molecular subtypes. Lifestyle seems related to these aggressive conditions and worse outcomes. The present study seeks to evaluate the effect of a hybrid multidisciplinary intervention for implementing a healthy lifestyle to modify the personal and internal exposome of young women with breast cancer. This randomized controlled experimental study with two groups:\n\nGroup 1: Hybrid multidisciplinary lifestyle education intervention. Group 2: Individualized hybrid multidisciplinary lifestyle interventions. The multidisciplinary lifestyle intervention program includes oncology, nutrition, physiotherapy, and psychology interventions.",[28],[692,693,694,27],"Multidisciplinary","Intervention","Lifestyle","2023-10-13",{"date":697,"type":52},"2023-10-19",{"date":699,"type":52},"2023-03-09",{"date":701,"type":21},"2028-12-31",{"name":703,"class":59},"Instituto Nacional de Cancerologia de Mexico",{"id":705,"slug":706,"hasResults":11,"nctId":707,"briefTitle":708,"officialTitle":709,"acronym":4,"eligibilityCriteria":710,"healthyVolunteers":11,"sex":101,"minAge":18,"maxAge":4,"enrollmentInfo":711,"targetDuration":4,"studyType":22,"phases":712,"briefSummary":713,"conditions":714,"keywords":715,"overallStatus":463,"whyStopped":4,"lastUpdateSubmitDate":717,"lastUpdatePostDateStruct":718,"startDateStruct":720,"completionDateStruct":722,"leadSponsor":724,"locationsCount":4},"100505532","phase-2-the-study-of-trilaciclib-combined-with-chemotherapy-on-the-neoadjuvant-therapy-of-tnbc-100505532","NCT05862610","The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC","A Prospective, Randomized, Controlled Phase II Clinical Study of Trilaciclib Combined With Standard Treatment Project As a Neoadjuvant Treatment For Triple Negative Breast Cancer","Inclusion Criteria:\n\n* Newly treated patients aged ≥ 18 years;\n* ECOG score 0-1;\n* Breast cancer meets the following standards:\n\n  1. Histologically confirmed invasive breast cancer\n  2. Tumor staging: cT2-4, cNany, cM0 or cT1, cN1-3, cM0;\n* Hormone (estrogen and progesterone) receptor negative tumors confirmed by histological or cytological records (defined as nuclear staining rate\\\u003C1% based on immunohistochemistry \\[IHC\\] evaluation) and Her-2 negative, non overexpressing tumors (based on IHC \\[0 or 1+\\] or in situ hybridization \\[ratio\\\u003C2.0\\] or average Her-2 gene copy number\\\u003C4 signals\u002Fnucleus);\n* Within the first two weeks of the screening period, no G-CSF, TPO, IL-11, ESA, iron, platelet transfusion, or blood transfusion have been used.\n* The functional level of the main organs must meet the following requirements:\n\n  1. Blood routine: Neutrophils (ANC)≥1.5×109\u002FL, platelet count (PLT)≥90×109\u002FL, hemoglobin (Hb)≥90g\u002FL\n  2. Blood biochemistry: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN, serum creatinine (Cr)≤1.5×ULN, bilirubin\\\u003C1.5 ULN;\n* For female patients who have not undergone menopause or surgical sterilization: During the treatment period and at least 7 months after the last dose in the study treatment, consent to abstinence or use effective contraceptive methods.\n* Volunteer join this study, sign an informed consent form, have good compliance, and are willing to cooperate with follow-up.\n\nExclusion Criteria:\n\n* Previously received anti-tumor treatment for any malignant tumor;\n* Subjects who are unable to accept or tolerate preoperative chemotherapy due to various reasons;\n* The patient has undergone major surgical procedures unrelated to breast cancer within 4 weeks before enrollment, or has not fully recovered from such surgical procedures;\n* Serious heart disease or discomfort, including but not limited to the following diseases:\n\n  1. A confirmed history of heart failure or systolic dysfunction (LVEF\\\u003C50%);\n  2. High risk uncontrolled arrhythmias, such as atrial tachycardia, resting heart rate\\>100bpm, significant ventricular arrhythmias (such as ventricular tachycardia) or higher-level atrioventricular block (such as Mobitz II second degree atrioventricular block or third degree atrioventricular block);\n  3. Angina pectoris requiring treatment with anti angina drugs;\n  4. Heart valve disease with clinical significance;\n  5. ECG shows transmural myocardial infarction;\n  6. Poor control of hypertension (systolic blood pressure\\>180mmHg and\u002For diastolic blood pressure\\>100mmHg)\n* Those with a known history of allergies to the drug components of this protocol;\n* Breastfeeding female patients, those with fertility and positive baseline pregnancy test results, or those of childbearing age who are unwilling to take effective contraceptive measures during the entire trial period and within 7 months after the last study medication;\n* Any other circumstances in which the researcher believes that the patient is not suitable to participate in this study.",{"count":366,"type":21},[73],"To evaluate the efficacy and safety of trilaciclib combined with standard treatment project as a neoadjuvant treatment for triple negative breast cancer",[28],[716],"Trilaciclib\u002FTNBC\u002FNeoadjuvant","2023-07-21",{"date":719,"type":52},"2023-07-24",{"date":721,"type":21},"2023-07-30",{"date":723,"type":21},"2027-06-30",{"name":725,"class":59},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"id":727,"slug":728,"hasResults":11,"nctId":729,"briefTitle":730,"officialTitle":730,"acronym":731,"eligibilityCriteria":732,"healthyVolunteers":11,"sex":101,"minAge":18,"maxAge":4,"enrollmentInfo":733,"targetDuration":4,"studyType":22,"phases":734,"briefSummary":735,"conditions":736,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":738,"lastUpdatePostDateStruct":739,"startDateStruct":741,"completionDateStruct":743,"leadSponsor":744,"locationsCount":60},"100472068","magnetic-marker-localization-for-occult-breast-cancer-and-target-axillary-dissection-in-node-positive-breast-cancer-post-neoadjuvant-chemotherapy-100472068","NCT05427071","Magnetic Marker Localization for Occult Breast Cancer and Target Axillary Dissection in Node-positive Breast Cancer Post-neoadjuvant Chemotherapy","MaCTAD","Inclusion Criteria:\n\n* All patients with cT1-3N1 invasive ductal carcinoma planned for neoadjuvant chemotherapy and\u002For target therapy\n* mentally competent to give informed consent\n* Agreed to proceed with curative operation after chemotherapy and tentatively keen for breast conservative surgery and targeted axillary dissection after neoadjuvant chemotherapy\n* Radiologically 1-3 ipsilateral axillary lymph node metastases confirmed by cytology or biopsy\n\nExclusion Criteria:\n\n* Presence of distant metastasis, inflammatory breast cancers, multi-centric breast cancers\n* History of previous ipsilateral axillary surgery or irradiation\n* Hypersensitivity to dextran compounds or iron\n* Iron overload disease\n* Pregnant or lactating patients\n* Patients with pacemaker or other implantable metallic devices in chest wall or prosthesis in shoulder\n* Mentally incompetent patients",{"count":319,"type":21},[24],"The use of neoadjuvant chemotherapy in breast cancer is expanding in the recent decade. Patients with good response to neoadjuvant chemotherapy could benefit from de-escalation of breast and axilla operation. However, breast tumor and involved axillary lymph node should be marked before the commencement of chemotherapy. This could facilitate subsequent operative planning and intraoperative assessment of disease response. This study aims to evaluate the feasibility of magnetic marker localization for non-palpable breast cancer and targeted axillary dissection in patients with node-positive breast cancer following neoadjuvant therapy",[28,737],"Chemotherapy Effect","2022-06-16",{"date":740,"type":52},"2022-06-22",{"date":742,"type":52},"2020-10-15",{"date":701,"type":21},{"name":745,"class":59},"The University of Hong Kong"]